Our findings suggest that IL-27 could have clinical value in identifying patients with peripheral artery disease with adverse prognosis, who may benefit from more intensive follow-up and more aggressive risk management/secondary prevention strategies, including high-intensity regimens of statins and ACE inhibitors. This evidence concerns the gene ACE and peripheral arterial disease.